{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T22:30:26Z","timestamp":1794004226023,"version":"4.8.0"},"reference-count":276,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,1,14]],"date-time":"2025-01-14T00:00:00Z","timestamp":1736812800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100006087","name":"Direcci\u00f3n General de Asuntos del Personal Acad\u00e9mico, Universidad Nacional Aut\u00f3noma de M\u00e9xico","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100006087","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005739","name":"Universidad Nacional Aut\u00f3noma de M\u00e9xico","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100005739","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:p>Drug repositioning, the practice of identifying novel applications for existing drugs beyond their originally intended medical indications, stands as a transformative strategy revolutionizing pharmaceutical productivity. In contrast to conventional drug development approaches, this innovative method has proven to be exceptionally effective. This is particularly relevant for cancer therapy, where the demand for groundbreaking treatments continues to grow. This review focuses on drug repositioning for ovarian cancer treatment, showcasing a comprehensive exploration grounded in thorough <jats:italic>in vitro<\/jats:italic> experiments across diverse cancer cell lines, which are validated through preclinical <jats:italic>in vivo<\/jats:italic> models. These insights not only shed light on the efficacy of these drugs but also expand in potential synergies with other pharmaceutical agents, favoring the development of cost-effective treatments for cancer patients.<\/jats:p>","DOI":"10.3389\/fonc.2024.1514120","type":"journal-article","created":{"date-parts":[[2025,1,14]],"date-time":"2025-01-14T06:12:39Z","timestamp":1736835159000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":9,"title":["Revolutionizing ovarian cancer therapy by drug repositioning for accelerated and cost-effective treatments"],"prefix":"10.3389","volume":"14","author":[{"given":"Edgar Yebran","family":"Villegas-Vazquez","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francisco P\u00e1vel","family":"Mar\u00edn-Carrasco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Octavio Daniel","family":"Reyes-Hern\u00e1ndez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea S.","family":"B\u00e1ez-Gonz\u00e1lez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lilia Patricia","family":"Bustamante-Montes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Teresita","family":"Padilla-Benavides","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura Itzel","family":"Quintas-Granados","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriela","family":"Figueroa-Gonz\u00e1lez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,1,14]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1155\/tswj.v2015.1","article-title":"Drug repositioning for gynecologic tumors: a new therapeutic strategy for cancer","volume":"2015","author":"Banno","year":"2015","journal-title":"Sci World J"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2014.3002","article-title":"Genomics-enabled drug repositioning and repurposing: insights from an IOM Roundtable activity","volume":"311","author":"Power","year":"2014","journal-title":"Jama"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2016.05.028","article-title":"Characterization of ovarian cancer cell lines as in vivo models for preclinical studies","volume":"142","author":"Hernandez","year":"2016","journal-title":"Gynecol Oncol"},{"key":"B4","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1186\/s13046-022-02486-z","article-title":"Harnessing preclinical models for the interrogation of ovarian cancer","volume":"41","author":"Qin","year":"2022","journal-title":"J Exp Clin Cancer Res"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.3390\/cancers11081098","article-title":"Cancer cell lines are useful model systems for medical research","volume":"11","author":"Mirabelli","year":"2019","journal-title":"Cancers (Basel)"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.2147\/CMAR.S302565","article-title":"Application of animal models in cancer research: recent progress and future prospects","volume":"13","author":"Li","year":"2021","journal-title":"Cancer Manag Res"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1095388","article-title":"Experimental mouse models for translational human cancer research","volume":"14","author":"Zhou","year":"2023","journal-title":"Front Immunol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1093\/ilar\/ily014","article-title":"Of mice, dogs, pigs, and men: choosing the appropriate model for immuno-oncology research","volume":"59","author":"Overgaard","year":"2018","journal-title":"ILAR J"},{"key":"B9","volume-title":"Berek and Hacker's gynecologic oncology","author":"Berek","year":"2010"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(13)62146-7","article-title":"Ovarian cancer","volume":"384","author":"Jayson","year":"2014","journal-title":"Lancet"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21660","article-title":"Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA: Cancer J Clin"},{"key":"B12","doi-asserted-by":"publisher","first-page":"2230","DOI":"10.3390\/cancers14092230","article-title":"Worldwide burden, risk factors, and temporal trends of ovarian cancer: A global study","volume":"14","author":"Huang","year":"2022","journal-title":"Cancers"},{"key":"B13","volume-title":"WHO classification of tumours of female reproductive organs. Monodermal teratomas and somatic-type tumours arising from a dermoid cyst","author":"Young","year":"2014"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(18)32552-2","article-title":"Epithelial ovarian cancer","volume":"393","author":"Lheureux","year":"2019","journal-title":"Lancet"},{"key":"B15","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13073-021-00952-5","article-title":"Distinct transcriptional programs stratify ovarian cancer cell lines into the five major histological subtypes","volume":"13","author":"Barnes","year":"2021","journal-title":"Genome Med"},{"key":"B16","volume-title":"World Health Organisation classification of tumours of the female reproductive organs","author":"Kurman","year":"2014"},{"key":"B17","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1097\/00000478-200404000-00009","article-title":"Grading ovarian serous carcinoma using a two-tier system","volume":"28","author":"Malpica","year":"2004","journal-title":"Am J Surg Pathol"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2019.12.033","article-title":"Low-grade serous ovarian cancer: state of the science","volume":"156","author":"Slomovitz","year":"2020","journal-title":"Gynecologic Oncol"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1097\/PAS.0000000000000693","article-title":"Low-grade serous carcinoma of the ovary","volume":"40","author":"Ahn","year":"2016","journal-title":"Am J Surg Pathol"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2021.10.078","article-title":"Clinical factors and biomarker profiles associated with patient outcome in endometrioid ovarian carcinoma-Emphasis on tumor grade","volume":"164","author":"Soovares","year":"2022","journal-title":"Gynecologic Oncol"},{"key":"B21","doi-asserted-by":"publisher","first-page":"4995","DOI":"10.1038\/s41467-020-18819-5","article-title":"Molecular stratification of endometrioid ovarian carcinoma predicts clinical outcome","volume":"11","author":"Hollis","year":"2020","journal-title":"Nat Commun"},{"key":"B22","doi-asserted-by":"publisher","first-page":"430","DOI":"10.1097\/PGP.0000000000000274","article-title":"An immunohistochemical algorithm for ovarian carcinoma typing","volume":"35","author":"K\u00f6bel","year":"2016","journal-title":"Int J Gynecological Pathol"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1097\/PAT.0b013e328348a6e7","article-title":"Morphological subtypes of ovarian carcinoma: a review with emphasis on new developments and pathogenesis","volume":"43","author":"McCluggage","year":"2011","journal-title":"Pathology"},{"key":"B24","doi-asserted-by":"publisher","first-page":"ijgc","DOI":"10.1136\/ijgc-2020-001656","article-title":"Clear cell carcinoma of the ovary: a clinical and molecular perspective","volume":"34","author":"Iida","year":"2020","journal-title":"Int J Gynecologic Cancer"},{"key":"B25","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1038\/s41379-020-0618-9","article-title":"Refined cut-off for TP53 immunohistochemistry improves prediction of TP53 mutation status in ovarian mucinous tumors: implications for outcome analyses","volume":"34","author":"Kang","year":"2021","journal-title":"Modern Pathol"},{"key":"B26","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1038\/nature10166","article-title":"Integrated genomic analyses of ovarian carcinoma","volume":"474","year":"2011","journal-title":"Nature"},{"key":"B27","article-title":"BRCA1 promoter region hypermethylation in ovarian carcinoma: a population-based study","volume":"60","author":"Baldwin","year":"2000","journal-title":"Cancer Res"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/94.18.1396","article-title":"Inactivation of BRCA1 and BRCA2 in ovarian cancer","volume":"94","author":"Hilton","year":"2002","journal-title":"J Natl Cancer Institute"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9440(10)64059-X","article-title":"Primary ovarian carcinomas display multiple methylator phenotypes involving known tumor suppressor genes","volume":"158","author":"Strathdee","year":"2001","journal-title":"Am J Pathol"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1002\/path.v202:2","article-title":"Expression of BRCA1 protein in benign, borderline, and Malignant epithelial ovarian neoplasms and its relationship to methylation and allelic loss of the BRCA1 gene","volume":"202","author":"Wang","year":"2004","journal-title":"J Pathology: A J Pathological Soc Great Britain Ireland"},{"key":"B31","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.ijgo.2013.10.001","article-title":"Staging classification for cancer of the ovary, fallopian tube, and peritoneum","volume":"124","author":"Prat","year":"2014","journal-title":"Int J Gynecology Obstetrics"},{"key":"B32","volume-title":"Ovarian Epithelial, Fallopian Tube, and Primary Peritoneal Cancer Treatment (PDQ\u00ae) Health Professional Version","author":"Height","year":"2024"},{"key":"B33","volume-title":"Ovarian Cancer Stages","author":"Society","year":"2020"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.2147\/IJWH.S197604","article-title":"Ovarian cancer in the world: epidemiology and risk factors","volume":"11","author":"Momenimovahed","year":"2019","journal-title":"Int J women's Health"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1086\/375033","article-title":"Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case series unselected for family history: a combined analysis of 22 studies","volume":"72","author":"Antoniou","year":"2003","journal-title":"Am J Hum Genet"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1007\/s10689-005-1838-3","article-title":"Gynecologic cancers in Lynch syndrome\/HNPCC","volume":"4","author":"Lu","year":"2005","journal-title":"Familial Cancer"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1080\/10937400701876095","article-title":"Risk factors for ovarian cancer: an overview with emphasis on hormonal factors","volume":"11","author":"Salehi","year":"2008","journal-title":"J Toxicol Environ Health Part B"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(07)61437-8","article-title":"Ovarian cancer and hormone replacement therapy\u2013Authors' reply","volume":"370","author":"Beral","year":"2007","journal-title":"Lancet"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(12)70322-4","article-title":"Ovarian cancer and smoking: individual participant meta-analysis including 28 114 women with ovarian cancer from 51 epidemiological studies","volume":"13","year":"2012","journal-title":"Lancet Oncol"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1158\/1940-6207.CAPR-13-0037","article-title":"Genital powder use and risk of ovarian cancer: a pooled analysis of 8,525 cases and 9,859 controls","volume":"6","author":"Terry","year":"2013","journal-title":"Cancer Prev Res"},{"key":"B41","doi-asserted-by":"publisher","first-page":"102912","DOI":"10.18632\/oncotarget.22076","article-title":"High-grade ovarian serous carcinoma patients exhibit profound alterations in lipid metabolism","volume":"8","author":"Braicu","year":"2017","journal-title":"Oncotarget"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1007\/s10552-017-0867-1","article-title":"History of hypertension, heart disease, and diabetes and ovarian cancer patient survival: evidence from the ovarian cancer association consortium","volume":"28","author":"Minlikeeva","year":"2017","journal-title":"Cancer causes control"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2014.09.004","article-title":"Diabetes mellitus and ovarian cancer: more complex than just increasing risk","volume":"135","author":"Shah","year":"2014","journal-title":"Gynecologic Oncol"},{"key":"B44","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/j.diabres.2017.04.005","article-title":"Diabetes mellitus and risk of ovarian cancer. A systematic review and meta-analysis of 15 cohort studies","volume":"130","author":"Zhang","year":"2017","journal-title":"Diabetes Res Clin Pract"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1677\/erc.1.01039","article-title":"Estrogen receptor-\u03b1 mediates gene expression changes and growth response in ovarian cancer cells exposed to estrogen","volume":"12","author":"O\u2019Donnell","year":"2005","journal-title":"Endocrine-related Cancer"},{"key":"B46","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12986-017-0176-4","article-title":"Case-control study of metabolic syndrome and ovarian cancer in Chinese population","volume":"14","author":"Chen","year":"2017","journal-title":"Nutr Metab"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-010-0855-8","article-title":"Myeloid-derived suppressor cells: more mechanisms for inhibiting antitumor immunity","volume":"59","author":"Ostrand-Rosenberg","year":"2010","journal-title":"Cancer immunology immunotherapy"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1097\/00001648-200003000-00006","article-title":"Factors related to inflammation of the ovarian epithelium and risk of ovarian cancer","volume":"11","author":"Ness","year":"2000","journal-title":"Epidemiology"},{"key":"B49","volume-title":"US cancer statistics data visualizations tool, based on November 2018 submission data (1999\u20132016): US Department of Health and Human Services, Centers for Disease Control and Prevention and National Cancer Institute","year":"2019"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2017.21926","article-title":"Screening for ovarian cancer: US preventive services task force recommendation statement","volume":"319","author":"Grossman","year":"2018","journal-title":"Jama"},{"key":"B51","doi-asserted-by":"publisher","first-page":"598","DOI":"10.1093\/aje\/kwp176","article-title":"Ovarian cancer risk factors in African-American and white women","volume":"170","author":"Moorman","year":"2009","journal-title":"Am J Epidemiol"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2020.07.008","article-title":"Incidence and mortality of ovarian cancer at the global, regional, and national levels, 1990\u20132017","volume":"159","author":"Zheng","year":"2020","journal-title":"Gynecologic Oncol"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.v151.9","article-title":"Ovarian cancer today and tomorrow: A global assessment by world region and Human Development Index using GLOBOCAN 2020","volume":"151","author":"Cabasag","year":"2022","journal-title":"Int J Cancer"},{"key":"B54","doi-asserted-by":"publisher","first-page":"47","DOI":"10.21037\/cco-20-34","article-title":"Epidemiology of ovarian cancer","volume":"9","author":"Gaona-Luviano","year":"2020","journal-title":"Chin Clin Oncol"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1097\/IGC.0000000000001118","article-title":"Ovarian cancer prevention, screening, and early detection: report from the 11th biennial ovarian cancer research symposium","volume":"27","author":"Chien","year":"2017","journal-title":"Int J Gynecologic Cancer"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1097\/AOG.0b013e318264f794","article-title":"Ten-year relative survival for epithelial ovarian cancer","volume":"120","author":"Baldwin","year":"2012","journal-title":"Obstetrics Gynecology"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.3332\/ecancer.2014.465","article-title":"Natural history of ovarian cancer","volume":"8","author":"Vargas","year":"2014","journal-title":"ecancermedicalscience"},{"key":"B58","volume-title":"Ovarian Cancer. Including Fallopian Tube Cancer and Primary Peritoneal Cancer. Version 2.2020","year":"2021"},{"key":"B59","doi-asserted-by":"publisher","first-page":"672","DOI":"10.1093\/annonc\/mdz062","article-title":"ESMO\u2013ESGO consensus conference recommendations on ovarian cancer: pathology and molecular biology, early and advanced stages, borderline tumours and recurrent disease","volume":"30","author":"Colombo","year":"2019","journal-title":"Ann Oncol"},{"key":"B60","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12885-018-4970-9","article-title":"Long-term mortality among women with epithelial ovarian cancer: a population-based study in British Columbia, Canada","volume":"18","author":"Arora","year":"2018","journal-title":"BMC cancer"},{"key":"B61","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3892\/etm.2021.10826","article-title":"Monensin suppresses cell proliferation and invasion in ovarian cancer by enhancing MEK1 SUMOylation","volume":"22","author":"Yao","year":"2021","journal-title":"Exp Ther Med"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.1126\/science.1088759","article-title":"Breast and ovarian cancer risks due to inherited mutations in BRCA1 and BRCA2","volume":"302","author":"King","year":"2003","journal-title":"Science"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/95.2.105","article-title":"International Collaborative Ovarian Neoplasm trial 1 and Adjuvant ChemoTherapy In Ovarian Neoplasm trial: two parallel randomized phase III trials of adjuvant chemotherapy in patients with early-stage ovarian carcinoma","volume":"95","year":"2003","journal-title":"J Natl Cancer Institute"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/95.2.113","article-title":"Impact of adjuvant chemotherapy and surgical staging in early-stage ovarian carcinoma: European Organisation for Research and Treatment of Cancer\u2013Adjuvant ChemoTherapy In Ovarian Neoplasm trial","volume":"95","author":"Trimbos","year":"2003","journal-title":"J Natl Cancer Institute"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdt333","article-title":"Newly diagnosed and relapsed epithelial ovarian carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"24","author":"Ledermann","year":"2013","journal-title":"Ann Oncol"},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1097-0142(19990115)85:2<418::AID-CNCR20>3.0.CO;2-9","article-title":"Quality of life of African-American and white long term breast carcinoma survivors","volume":"85","author":"Ashing-Giwa","year":"1999","journal-title":"Cancer: Interdiscip Int J Am Cancer Soc"},{"key":"B67","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1056\/NEJM199601043340101","article-title":"Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer","volume":"334","author":"McGuire","year":"1996","journal-title":"New Engl J Med"},{"key":"B68","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2003.02.153","article-title":"Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study","volume":"21","author":"Ozols","year":"2003","journal-title":"J Clin Oncol"},{"key":"B69","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djh323","article-title":"Phase III randomized trial of docetaxel\u2013carboplatin versus paclitaxel\u2013carboplatin as first-line chemotherapy for ovarian carcinoma","volume":"96","author":"Vasey","year":"2004","journal-title":"J Natl Cancer Institute"},{"key":"B70","doi-asserted-by":"publisher","first-page":"304","DOI":"10.20517\/cdr.2021.147","article-title":"Mechanisms of chemotherapy resistance in ovarian cancer","volume":"5","author":"Ortiz","year":"2022","journal-title":"Cancer Drug Resistance"},{"key":"B71","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.v125.s24","article-title":"New strategies in ovarian cancer treatment","volume":"125","author":"Lee","year":"2019","journal-title":"Cancer"},{"key":"B72","doi-asserted-by":"publisher","DOI":"10.1111\/jog.2015.41.issue-10","article-title":"Epithelial ovarian cancer with CD117 phenotype is highly aggressive and resistant to chemotherapy","volume":"41","author":"Conic","year":"2015","journal-title":"J Obstetrics Gynaecology Res"},{"key":"B73","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(12)70572-7","article-title":"Selumetinib in women with recurrent low-grade serous carcinoma of the ovary or peritoneum: an open-label, single-arm, phase 2 study","volume":"14","author":"Farley","year":"2013","journal-title":"Lancet Oncol"},{"key":"B74","doi-asserted-by":"publisher","DOI":"10.1177\/1740774517725697","article-title":"Testing many treatments within a single protocol over 10 years at MRC Clinical Trials Unit at UCL: Multi-arm, multi-stage platform, umbrella and basket protocols","volume":"14","author":"Parmar","year":"2017","journal-title":"Clin trials"},{"key":"B75","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2018.02.005","article-title":"Moving forward with actionable therapeutic targets and opportunities in endometrial cancer: a NCI clinical trials planning meeting report","volume":"149","author":"Lheureux","year":"2018","journal-title":"Gynecologic Oncol"},{"key":"B76","doi-asserted-by":"publisher","first-page":"41","DOI":"10.3390\/cancers9050041","article-title":"Targeting the ATR-CHK1 axis in cancer therapy","volume":"9","author":"Rundle","year":"2017","journal-title":"Cancers"},{"key":"B77","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.ctrv.2018.09.003","article-title":"Restored replication fork stabilization, a mechanism of PARP inhibitor resistance, can be overcome by cell cycle checkpoint inhibition","volume":"71","author":"Haynes","year":"2018","journal-title":"Cancer Treat Rev"},{"key":"B78","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-16-0083","article-title":"Achieving precision death with cell-cycle inhibitors that target DNA replication and repair","volume":"23","author":"Lin","year":"2017","journal-title":"Clin Cancer Res"},{"key":"B79","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(18)30009-3","article-title":"Prexasertib, a cell cycle checkpoint kinase 1 and 2 inhibitor, in BRCA wild-type recurrent high-grade serous ovarian cancer: a first-in-class proof-of-concept phase 2 study","volume":"19","author":"Lee","year":"2018","journal-title":"Lancet Oncol"},{"key":"B80","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2017.08.013","article-title":"DNA damage response inhibitors: Mechanisms and potential applications in cancer therapy","volume":"60","author":"Carrassa","year":"2017","journal-title":"Cancer Treat Rev"},{"key":"B81","doi-asserted-by":"publisher","first-page":"3409","DOI":"10.1200\/JCO.2014.60.4009","article-title":"Phase I study of single-agent AZD1775 (MK-1775), a Wee1 kinase inhibitor, in patients with refractory solid tumors","volume":"33","author":"Do","year":"2015","journal-title":"J Clin Oncol"},{"key":"B82","doi-asserted-by":"publisher","DOI":"10.1158\/1541-7786.MCR-17-0455","article-title":"PARP1 trapping and DNA replication stress enhance radiosensitization with combined WEE1 and PARP inhibitors","volume":"16","author":"Parsels","year":"2018","journal-title":"Mol Cancer Res"},{"key":"B83","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1104390","article-title":"Incorporation of bevacizumab in the primary treatment of ovarian cancer","volume":"365","author":"Burger","year":"2011","journal-title":"New Engl J Med"},{"key":"B84","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(15)00086-8","article-title":"Standard chemotherapy with or without bevacizumab for women with newly diagnosed ovarian cancer (ICON7): overall survival results of a phase 3 randomised trial","volume":"16","author":"Oza","year":"2015","journal-title":"Lancet Oncol"},{"key":"B85","doi-asserted-by":"publisher","first-page":"2039","DOI":"10.1200\/JCO.2012.42.0505","article-title":"OCEANS: a randomized, double-blind, placebo-controlled phase III trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent epithelial ovarian, primary peritoneal, or fallopian tube cancer","volume":"30","author":"Aghajanian","year":"2012","journal-title":"J Clin Oncol"},{"key":"B86","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(17)30279-6","article-title":"Bevacizumab and paclitaxel\u2013carboplatin chemotherapy and secondary cytoreduction in recurrent, platinum-sensitive ovarian cancer (NRG Oncology\/Gynecologic Oncology Group study GOG-0213): a multicentre, open-label, randomised, phase 3 trial","volume":"18","author":"Coleman","year":"2017","journal-title":"Lancet Oncol"},{"key":"B87","doi-asserted-by":"publisher","DOI":"10.1097\/01.ogx.0000452705.82050.e4","article-title":"Bevacizumab combined with chemotherapy for platinum-resistant recurrent ovarian cancer: the AURELIA open-label randomized phase III trial","volume":"69","author":"Pujade-Lauraine","year":"2014","journal-title":"Obstetrical Gynecological Survey"},{"key":"B88","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(14)70391-2","article-title":"Combination cediranib and olaparib versus olaparib alone for women with recurrent platinum-sensitive ovarian cancer: a randomised phase 2 study","volume":"15","author":"Liu","year":"2014","journal-title":"Lancet Oncol"},{"key":"B89","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdz018","article-title":"Overall survival and updated progression-free survival outcomes in a randomized phase II study of combination cediranib and olaparib versus olaparib in relapsed platinum-sensitive ovarian cancer","volume":"30","author":"Liu","year":"2019","journal-title":"Ann Oncol"},{"key":"B90","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1209124","article-title":"Trastuzumab emtansine for HER2-positive advanced breast cancer","volume":"367","author":"Verma","year":"2012","journal-title":"New Engl J Med"},{"key":"B91","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2015.63.2596","article-title":"A randomized, double-blind, placebo-controlled, phase III study to assess efficacy and safety of weekly farletuzumab in combination with carboplatin and taxane in patients with ovarian cancer in first platinum-sensitive relapse","volume":"34","author":"Vergote","year":"2016","journal-title":"J Clin Oncol"},{"key":"B92","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.MCT-14-1095","article-title":"IMGN853, a folate receptor-\u03b1 (FR\u03b1)\u2013targeting antibody\u2013drug conjugate, exhibits potent targeted antitumor activity against FR\u03b1-expressing tumors","volume":"14","author":"Ab","year":"2015","journal-title":"Mol Cancer Ther"},{"key":"B93","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2017.08.015","article-title":"Characterization of folate receptor alpha (FR\u03b1) expression in archival tumor and biopsy samples from relapsed epithelial ovarian cancer patients: A phase I expansion study of the FR\u03b1-targeting antibody-drug conjugate mirvetuximab soravtansine","volume":"147","author":"Martin","year":"2017","journal-title":"Gynecologic Oncol"},{"key":"B94","doi-asserted-by":"publisher","DOI":"10.2217\/fon-2017-0646","article-title":"FORWARD I: a Phase III study of mirvetuximab soravtansine versus chemotherapy in platinum-resistant ovarian cancer","volume":"14","author":"Moore","year":"2018","journal-title":"Future Oncol"},{"key":"B95","doi-asserted-by":"publisher","first-page":"2361","DOI":"10.3390\/cells11152361","article-title":"The role of ATR inhibitors in ovarian cancer: investigating predictive biomarkers of response","volume":"11","author":"Bradbury","year":"2022","journal-title":"Cells"},{"key":"B96","doi-asserted-by":"publisher","first-page":"11497","DOI":"10.2147\/OTT.S195552","article-title":"Role of olaparib as maintenance treatment for ovarian cancer: the evidence to date","volume":"12","author":"Montemorano","year":"2019","journal-title":"OncoTargets Ther"},{"key":"B97","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1634\/theoncologist.2009-0317","article-title":"Bevacizumab","volume":"15","author":"Kazazi-Hyseni","year":"2010","journal-title":"oncologist"},{"key":"B98","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1200694","article-title":"Safety and activity of anti\u2013PD-L1 antibody in patients with advanced cancer","volume":"366","author":"Brahmer","year":"2012","journal-title":"New Engl J Med"},{"key":"B99","volume-title":"Endotext","author":"Feingold","year":"2000"},{"key":"B100","doi-asserted-by":"publisher","DOI":"10.1038\/343425a0","article-title":"Regulation of the mevalonate pathway","volume":"343","author":"Goldstein","year":"1990","journal-title":"Nature"},{"key":"B101","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2402476","article-title":"HMG-CoA reductase inhibitors and the Malignant cell: the statin family of drugs as triggers of tumor-specific apoptosis","volume":"16","author":"Wong","year":"2002","journal-title":"Leukemia"},{"key":"B102","first-page":"2478","article-title":"Atorvastatin exhibits anti-tumorigenic and anti-metastatic effects in ovarian cancer in vitro","volume":"7","author":"Jones","year":"2017","journal-title":"Am J Cancer Res"},{"key":"B103","doi-asserted-by":"publisher","DOI":"10.4161\/cbt.12.8.15978","article-title":"Atorvastatin induces autophagy in prostate cancer PC3 cells through activation of LC3 transcription","volume":"12","author":"Toepfer","year":"2011","journal-title":"Cancer Biol Ther"},{"key":"B104","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-14-3368","article-title":"Mevalonate pathway antagonist suppresses formation of serous tubal intraepithelial carcinoma and ovarian carcinoma in mouse models","volume":"21","author":"Kobayashi","year":"2015","journal-title":"Clin Cancer Res"},{"key":"B105","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/1471-2407-10-103","article-title":"Lovastatin induces apoptosis of ovarian cancer cells and synergizes with doxorubicin: potential therapeutic relevance","volume":"10","author":"Martirosyan","year":"2010","journal-title":"BMC Cancer"},{"key":"B106","doi-asserted-by":"publisher","first-page":"47343","DOI":"10.18632\/oncotarget.10121","article-title":"Ovarian tumour growth is characterized by mevalonate pathway gene signature in an orthotopic, syngeneic model of epithelial ovarian cancer","volume":"7","author":"Greenaway","year":"2016","journal-title":"Oncotarget"},{"key":"B107","doi-asserted-by":"publisher","first-page":"946","DOI":"10.18632\/oncotarget.5834","article-title":"The HMG-CoA reductase inhibitor, simvastatin, exhibits anti-metastatic and anti-tumorigenic effects in ovarian cancer","volume":"7","author":"Stine","year":"2016","journal-title":"Oncotarget"},{"key":"B108","doi-asserted-by":"publisher","first-page":"72147","DOI":"10.18632\/oncotarget.20046","article-title":"Drug repositioning of mevalonate pathway inhibitors as antitumor agents for ovarian cancer","volume":"8","author":"Kobayashi","year":"2017","journal-title":"Oncotarget"},{"key":"B109","article-title":"Alendronate inhibits lysophosphatidic acid-induced migration of human ovarian cancer cells by attenuating the activation of rho","volume":"62","author":"Sawada","year":"2002","journal-title":"Cancer Res"},{"key":"B110","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.540.65.2","article-title":"Alendronate inhibits intraperitoneal dissemination in in vivo ovarian cancer model","volume":"65","author":"Hashimoto","year":"2005","journal-title":"Cancer Res"},{"key":"B111","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1204061","article-title":"Fracture risk and zoledronic acid therapy in men with osteoporosis","volume":"367","author":"Boonen","year":"2012","journal-title":"New Engl J Med"},{"key":"B112","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-144-4-200602210-00005","article-title":"Zoledronic acid prevents bone loss after liver transplantation: a randomized, double-blind, placebo-controlled trial","volume":"144","author":"Crawford","year":"2006","journal-title":"Ann Internal Med"},{"key":"B113","doi-asserted-by":"publisher","DOI":"10.1016\/S0093-7754(01)90261-1","article-title":"Zoledronic acid in the treatment of hypercalcemia of Malignancy: results of the international clinical development program","volume":"28","author":"Major","year":"2001","journal-title":"Semin Oncol"},{"key":"B114","article-title":"Zoledronic acid versus pamidronate in the treatment of skeletal metastases in patients with breast cancer or osteolytic lesions of multiple myeloma: a phase III, double-blind, comparative trial","volume":"7","author":"Rosen","year":"2001","journal-title":"Cancer J (Sudbury Mass)"},{"key":"B115","doi-asserted-by":"publisher","DOI":"10.1684\/ecn.2009.0159","article-title":"Combined gossypol and zoledronic acid treatment results in synergistic induction of cell death and regulates angiogenic molecules in ovarian cancer cells","volume":"20","author":"Atmaca","year":"2009","journal-title":"Eur Cytokine Network"},{"key":"B116","doi-asserted-by":"publisher","DOI":"10.1097\/01.cad.0000215058.85813.02","article-title":"Synergistic antimyeloma effects of zoledronate and simvastatin","volume":"17","author":"Schmidmaier","year":"2006","journal-title":"Anti-cancer Drugs"},{"key":"B117","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/1471-2407-9-38","article-title":"Activity of mevalonate pathway inhibitors against breast and ovarian cancers in the ATP-based tumour chemosensitivity assay","volume":"9","author":"Knight","year":"2009","journal-title":"BMC Cancer"},{"key":"B118","doi-asserted-by":"publisher","first-page":"11029","DOI":"10.18632\/oncotarget.v5i22","article-title":"Mitochondria as new therapeutic targets for eradicating cancer stem cells: Quantitative proteomics and functional validation via MCT1\/2 inhibition","volume":"5","author":"Lamb","year":"2014","journal-title":"Oncotarget"},{"key":"B119","doi-asserted-by":"publisher","first-page":"4569","DOI":"10.18632\/oncotarget.3174","article-title":"Antibiotics that target mitochondria effectively eradicate cancer stem cells, across multiple tumor types: treating cancer like an infectious disease","volume":"6","author":"Lamb","year":"2015","journal-title":"Oncotarget"},{"key":"B120","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-09-2994","article-title":"Metformin selectively targets cancer stem cells, and acts together with chemotherapy to block tumor growth and prolong remission","volume":"69","author":"Hirsch","year":"2009","journal-title":"Cancer Res"},{"key":"B121","doi-asserted-by":"publisher","DOI":"10.1155\/2012\/928127","article-title":"Metformin: an emerging new therapeutic option for targeting cancer stem cells and metastasis","volume":"2012","author":"Rattan","year":"2012","journal-title":"J Oncol"},{"key":"B122","doi-asserted-by":"publisher","DOI":"10.1155\/2022\/7150204","article-title":"Clinical efficacy analysis of biofeedback electrical stimulation combined with doxycycline in the treatment of type IIIA chronic prostatitis","volume":"2022","author":"Sun","year":"2022","journal-title":"Evidence-Based Complementary Altern Med"},{"key":"B123","doi-asserted-by":"publisher","DOI":"10.1177\/0897190016642362","article-title":"Successful doxycycline therapy in a patient with Escherichia coli and multidrug-resistant Klebsiella pneumoniae urinary tract infection","volume":"30","author":"White","year":"2017","journal-title":"J Pharm Pract"},{"key":"B124","doi-asserted-by":"publisher","DOI":"10.1111\/j.1540-9740.2003.03014.x","article-title":"Subantimicrobial dose doxycycline for acne and rosacea","volume":"2","author":"Joseph","year":"2003","journal-title":"SKINmed: Dermatol Clinician"},{"key":"B125","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9440(10)64929-2","article-title":"Doxycycline modulates smooth muscle cell growth, migration, and matrix remodeling after arterial injury","volume":"160","author":"Bendeck","year":"2002","journal-title":"Am J Pathol"},{"key":"B126","doi-asserted-by":"publisher","DOI":"10.1016\/j.stemcr.2014.06.013","article-title":"Doxycycline enhances survival and self-renewal of human pluripotent stem cells","volume":"3","author":"Chang","year":"2014","journal-title":"Stem Cell Rep"},{"key":"B127","doi-asserted-by":"publisher","DOI":"10.1128\/aac.47.11.3630-3633.2003","article-title":"Doxycycline is anti-inflammatory and inhibits staphylococcal exotoxin-induced cytokines and chemokines","volume":"11","author":"Krakauer","year":"2003","journal-title":"Antimicrob Agents Chemother"},{"key":"B128","first-page":"3995","article-title":"Doxycycline induces apoptosis in PANC-1 pancreatic cancer cells","volume":"29","author":"Son","year":"2009","journal-title":"Anticancer Res"},{"key":"B129","article-title":"Doxycycline decreases tumor burden in a bone metastasis model of human breast cancer","volume":"62","author":"Duivenvoorden","year":"2002","journal-title":"Cancer Res"},{"key":"B130","doi-asserted-by":"publisher","DOI":"10.1016\/j.oraloncology.2009.11.013","article-title":"Anti-invasion and anti-tumor growth effect of doxycycline treatment for human oral squamous-cell carcinoma\u2013in vitro and in vivo studies","volume":"46","author":"Shen","year":"2010","journal-title":"Oral Oncol"},{"key":"B131","doi-asserted-by":"publisher","DOI":"10.1128\/MMBR.65.2.232-260.2001","article-title":"Tetracycline antibiotics: mode of action, applications, molecular biology, and epidemiology of bacterial resistance","volume":"65","author":"Chopra","year":"2001","journal-title":"Microbiol Mol Biol Rev"},{"key":"B132","article-title":"Protein synthesis inhibitors and miscellaneous antibacterial agents","volume-title":"Goodman and Gilman's the pharmacological basis of therapeutics","author":"MacDougall","year":"2011"},{"key":"B133","doi-asserted-by":"publisher","DOI":"10.1378\/chest.52.2.220","article-title":"Treatment of paragonimiasis with bithionol and bithionol sulfoxide","volume":"52","author":"Yang","year":"1967","journal-title":"Dis Chest"},{"key":"B134","doi-asserted-by":"publisher","DOI":"10.1021\/acsinfecdis.3c00257","article-title":"Bithionol restores sensitivity of multidrug-resistant gram-negative bacteria to colistin with antimicrobial and anti-biofilm effects","volume":"9","author":"Guo","year":"2023","journal-title":"ACS Infect Dis"},{"key":"B135","doi-asserted-by":"publisher","first-page":"31","DOI":"10.3390\/mps2020031","article-title":"High efficiency drug repurposing design for new antifungal agents","volume":"2","author":"Kim","year":"2019","journal-title":"Methods Protoc"},{"key":"B136","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/1471-2407-14-61","article-title":"Bithionol inhibits ovarian cancer cell growth in vitro-studies on mechanism (s) of action","volume":"14","author":"Ayyagari","year":"2014","journal-title":"BMC Cancer"},{"key":"B137","article-title":"Expression and transcriptional regulation of the PD-I\u03b1\/autotaxin gene in neuroblastoma","volume":"57","author":"Kawagoe","year":"1997","journal-title":"Cancer Res"},{"key":"B138","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1593\/neo.04535","article-title":"Gene expression profile of glioblastoma multiforme invasive phenotype points to new therapeutic targets","volume":"7","author":"Hoelzinger","year":"2005","journal-title":"Neoplasia"},{"key":"B139","doi-asserted-by":"publisher","DOI":"10.1054\/bjoc.2001.2074","article-title":"Identification of human renal cell carcinoma associated genes by suppression subtractive hybridization","volume":"85","author":"Stassar","year":"2001","journal-title":"Br J Cancer"},{"key":"B140","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.v109:6","article-title":"Expression, regulation and function of autotaxin in thyroid carcinomas","volume":"109","author":"Kehlen","year":"2004","journal-title":"Int J Cancer"},{"key":"B141","doi-asserted-by":"publisher","DOI":"10.1023\/A:1020950420196","article-title":"Expression of autotaxin (NPP-2) is closely linked to invasiveness of breast cancer cells","volume":"19","author":"Yang","year":"2002","journal-title":"Clin Exp metastasis"},{"key":"B142","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/1476-4598-9-71","article-title":"Autotaxin expression and its connection with the TNF-alpha-NF-\u03baB axis in human hepatocellular carcinoma","volume":"9","author":"Wu","year":"2010","journal-title":"Mol Cancer"},{"key":"B143","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccr.2009.03.027","article-title":"Expression of autotaxin and lysophosphatidic acid receptors increases mammary tumorigenesis, invasion, and metastases","volume":"15","author":"Liu","year":"2009","journal-title":"Cancer Cell"},{"key":"B144","doi-asserted-by":"publisher","DOI":"10.1007\/s13277-012-0433-0","article-title":"Opposite roles of LPA 1 and LPA 3 on cell motile and invasive activities of pancreatic cancer cells","volume":"33","author":"Kato","year":"2012","journal-title":"Tumor Biol"},{"key":"B145","doi-asserted-by":"publisher","DOI":"10.1038\/sj.onc.1203263","article-title":"Autotaxin (ATX), a potent tumor motogen, augments invasive and metastatic potential of ras-transformed cells","volume":"19","author":"Nam","year":"2000","journal-title":"Oncogene"},{"key":"B146","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-18-1212","article-title":"A stromal lysolipid\u2013autotaxin signaling axis promotes pancreatic tumor progression","volume":"9","author":"Auciello","year":"2019","journal-title":"Cancer Discovery"},{"key":"B147","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djn378","article-title":"Lysophosphatidic acid receptors determine tumorigenicity and aggressiveness of ovarian cancer cells","volume":"100","author":"Yu","year":"2008","journal-title":"JNCI: J Natl Cancer Institute"},{"key":"B148","article-title":"Autotaxin (NPP-2), a metastasis-enhancing motogen, is an angiogenic factor","volume":"61","author":"Nam","year":"2001","journal-title":"Cancer Res"},{"key":"B149","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/93.10.762","article-title":"Lysophosphatidic acid induction of vascular endothelial growth factor expression in human ovarian cancer cells","volume":"93","author":"Hu","year":"2001","journal-title":"J Natl Cancer Institute"},{"key":"B150","doi-asserted-by":"publisher","DOI":"10.1016\/S0304-3835(02)00713-9","article-title":"Expression of lysophosphatidic acid receptors and vascular endothelial growth factor mediating lysophosphatidic acid in the development of human ovarian cancer","volume":"192","author":"Fujita","year":"2003","journal-title":"Cancer Lett"},{"key":"B151","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1097\/CAD.0000000000000364","article-title":"Assessment of the anti-tumor potential of Bithionol in vivo using a xenograft model of ovarian cancer","volume":"27","author":"Ayyagari","year":"2016","journal-title":"Anti-cancer Drugs"},{"key":"B152","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/45.3.371","article-title":"Antifungal activity of itraconazole compared with hydroxy-itraconazole in vitro","volume":"45","author":"Odds","year":"2000","journal-title":"J Antimicrobial Chemotherapy"},{"key":"B153","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-11-0691","article-title":"Itraconazole inhibits angiogenesis and tumor growth in non\u2013small cell lung cancer","volume":"71","author":"Aftab","year":"2011","journal-title":"Cancer Res"},{"key":"B154","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1007\/s00432-019-03117-5","article-title":"Hedgehog pathway\u201d: a potential target of itraconazole in the treatment of cancer","volume":"146","author":"Wei","year":"2020","journal-title":"J Cancer Res Clin Oncol"},{"key":"B155","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1038\/s41419-020-02742-0","article-title":"Itraconazole inhibits the Hedgehog signaling pathway thereby inducing autophagy-mediated apoptosis of colon cancer cells","volume":"11","author":"Deng","year":"2020","journal-title":"Cell Death Dis"},{"key":"B156","doi-asserted-by":"publisher","DOI":"10.3332\/ecancer.2015.521","article-title":"Repurposing Drugs in Oncology (ReDO)\u2014itraconazole as an anti-cancer agent","volume":"9","author":"Pantziarka","year":"2015","journal-title":"Ecancermedicalscience"},{"key":"B157","article-title":"Impact of combination chemotherapy with itraconazole on survival of patients with refractory ovarian cancer","volume":"34","author":"Tsubamoto","year":"2014","journal-title":"Anticancer Res"},{"key":"B158","doi-asserted-by":"publisher","DOI":"10.1124\/mol.108.053363","article-title":"An ivermectin-sensitive glutamate-gated chloride channel from the parasitic nematode Haemonchus contortus","volume":"75","author":"McCavera","year":"2009","journal-title":"Mol Pharmacol"},{"key":"B159","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1011983107","article-title":"Ivermectin disrupts the function of the excretory-secretory apparatus in microfilariae of Brugia malayi","volume":"107","author":"Moreno","year":"2010","journal-title":"Proc Natl Acad Sci"},{"key":"B160","article-title":"Ivermectin inactivates the kinase PAK1 and blocks the PAK1-dependent growth of human ovarian cancer and NF2 tumor cell lines","volume":"3","author":"Hashimoto","year":"2009","journal-title":"Drug Discovery Ther"},{"key":"B161","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1007\/s13167-020-00209-y","article-title":"Anti-parasite drug ivermectin can suppress ovarian cancer by regulating lncRNA-EIF4A3-mRNA axes","volume":"11","author":"Li","year":"2020","journal-title":"EPMA J"},{"key":"B162","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjms.2019.11.001","article-title":"Ivermectin augments the in vitro and in vivo efficacy of cisplatin in epithelial ovarian cancer by suppressing Akt\/mTOR signaling","volume":"359","author":"Zhang","year":"2020","journal-title":"Am J Med Sci"},{"key":"B163","doi-asserted-by":"publisher","DOI":"10.1007\/s00280-020-04041-z","article-title":"Antitumor effects of ivermectin at clinically feasible concentrations support its clinical development as a repositioned cancer drug","volume":"85","author":"Juarez","year":"2020","journal-title":"Cancer Chemotherapy Pharmacol"},{"key":"B164","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1517188113","article-title":"Dysregulated YAP1\/TAZ and TGF-\u03b2 signaling mediate hepatocarcinogenesis in Mob1a\/1b-deficient mice","volume":"113","author":"Nishio","year":"2016","journal-title":"Proc Natl Acad Sci"},{"key":"B165","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0605579103","article-title":"Transforming properties of YAP, a candidate oncogene on the chromosome 11q22 amplicon","volume":"103","author":"Overholtzer","year":"2006","journal-title":"Proc Natl Acad Sci"},{"key":"B166","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2006.05.030","article-title":"Identification and validation of oncogenes in liver cancer using an integrative oncogenomic approach","volume":"125","author":"Zender","year":"2006","journal-title":"Cell"},{"key":"B167","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-10-2467","article-title":"Yes-associated protein 1 exhibits oncogenic property in gastric cancer and its nuclear accumulation associates with poor prognosis","volume":"17","author":"Kang","year":"2011","journal-title":"Clin Cancer Res"},{"key":"B168","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0152712","article-title":"Correction: YAP promotes ovarian cancer cell tumorigenesis and is indicative of a poor prognosis for ovarian cancer patients","volume":"11","author":"Xia","year":"2016","journal-title":"PloS One"},{"key":"B169","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1705441114","article-title":"In vivo loss-of-function screens identify KPNB1 as a new druggable oncogene in epithelial ovarian cancer","volume":"114","author":"Kodama","year":"2017","journal-title":"Proc Natl Acad Sci"},{"key":"B170","doi-asserted-by":"publisher","first-page":"105207","DOI":"10.1016\/j.phrs.2020.105207","article-title":"Ivermectin, a potential anticancer drug derived from an antiparasitic drug","volume":"163","author":"Tang","year":"2021","journal-title":"Pharmacol Res"},{"key":"B171","doi-asserted-by":"publisher","DOI":"10.3802\/jgo.2019.30.e10","article-title":"Current state and outlook for drug repositioning anticipated in the field of ovarian cancer","volume":"30","author":"Kobayashi","year":"2019","journal-title":"J gynecologic Oncol"},{"key":"B172","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2020.10.010","article-title":"Potential and mechanism of mebendazole for treatment and maintenance of ovarian cancer","volume":"160","author":"Elayapillai","year":"2021","journal-title":"Gynecologic Oncol"},{"key":"B173","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2009-09-243055","article-title":"The antihelmintic flubendazole inhibits microtubule function through a mechanism distinct from Vinca alkaloids and displays preclinical activity in leukemia and myeloma","volume":"115","author":"Spagnuolo","year":"2010","journal-title":"Blood J Am Soc Hematol"},{"key":"B174","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41598-018-30158-6","article-title":"Fenbendazole acts as a moderate microtubule destabilizing agent and causes cancer cell death by modulating multiple cellular pathways","volume":"8","author":"Dogra","year":"2018","journal-title":"Sci Rep"},{"key":"B175","doi-asserted-by":"publisher","DOI":"10.1158\/1541-7786.MCR-07-2159","article-title":"Mebendazole induces apoptosis via Bcl-2 inactivation in chemoresistant melanoma cells","volume":"6","author":"Doudican","year":"2008","journal-title":"Mol Cancer Res"},{"key":"B176","doi-asserted-by":"publisher","first-page":"17407","DOI":"10.18632\/aging.203232","article-title":"Antiparasitic mebendazole (MBZ) effectively overcomes cisplatin resistance in human ovarian cancer cells by inhibiting multiple cancer-associated signaling pathways","volume":"13","author":"Huang","year":"2021","journal-title":"Aging (Albany NY)"},{"key":"B177","doi-asserted-by":"publisher","DOI":"10.1161\/01.RES.83.11.1097","article-title":"Peroxisome proliferator-activated receptor gamma activators inhibit gene expression and migration in human vascular smooth muscle cells","volume":"83","author":"Marx","year":"1998","journal-title":"Circ Res"},{"key":"B178","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1038\/34178","article-title":"The peroxisome proliferator-activated receptor-\u03b3 is a negative regulator of macrophage activation","volume":"391","author":"Ricote","year":"1998","journal-title":"Nature"},{"key":"B179","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.274.13.9116","article-title":"Peroxisome proliferator-activated receptor \u03b3 ligands are potent inhibitors of angiogenesis in vitro and in vivo","volume":"274","author":"Xin","year":"1999","journal-title":"J Biol Chem"},{"key":"B180","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1530\/rep.1.00730","article-title":"Effects of luteinizing hormone on peroxisome proliferator-activated receptor \u03b3 in the rat ovary before and after the gonadotropin surge","volume":"131","author":"Banerjee","year":"2006","journal-title":"Reproduction"},{"key":"B181","doi-asserted-by":"publisher","DOI":"10.1093\/carcin\/bgh160","article-title":"PPAR\u03b3 influences susceptibility to DMBA-induced mammary, ovarian and skin carcinogenesis","volume":"25","author":"Nicol","year":"2004","journal-title":"Carcinogenesis"},{"key":"B182","article-title":"The effect of dietary fat on the rapid development of mammary tumors induced by 7, 12-dimethylbenz (a) anthracene in SENCAR mice","volume":"52","author":"Fischer","year":"1992","journal-title":"Cancer Res"},{"key":"B183","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1593\/neo.06433","article-title":"Cellular, molecular consequences of peroxisome proliferator-activated receptor-\u03b4 activation in ovarian cancer cells","volume":"8","author":"Vignati","year":"2006","journal-title":"Neoplasia"},{"key":"B184","doi-asserted-by":"publisher","DOI":"10.1016\/S1567-5769(02)00057-7","article-title":"PPAR and immune system\u2014what do we know","volume":"2","author":"Zhang","year":"2002","journal-title":"Int Immunopharmacol"},{"key":"B185","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.MCT-06-0184","article-title":"1, 1-Bis (3\u2032-indolyl)-1-(p-substituted phenyl) methanes inhibit ovarian cancer cell growth through peroxisome proliferator\u2013activated receptor\u2013dependent and independent pathways","volume":"5","author":"Lei","year":"2006","journal-title":"Mol Cancer Ther"},{"key":"B186","doi-asserted-by":"publisher","DOI":"10.3892\/or.18.4.833","article-title":"Peroxisome proliferator-activated receptor \u03b1 and \u03b3 ligands inhibit the growth of human ovarian cancer","volume":"18","author":"Shigeto","year":"2007","journal-title":"Oncol Rep"},{"key":"B187","doi-asserted-by":"publisher","DOI":"10.1016\/j.tox.2009.11.020","article-title":"Opposite effects of two thiazolidinediones, ciglitazone and troglitazone, on proteinase-activated receptor-1-triggered prostaglandin E2 release","volume":"268","author":"Takaoka","year":"2010","journal-title":"Toxicology"},{"key":"B188","doi-asserted-by":"publisher","DOI":"10.1016\/j.plefa.2007.05.006","article-title":"Ciglitazone mediates COX-2 dependent suppression of PGE2 in human non-small cell lung cancer cells","volume":"77","author":"Hazra","year":"2007","journal-title":"Prostaglandins leukotrienes essential Fatty Acids"},{"key":"B189","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.ejphar.2014.09.013","article-title":"Ciglitazone enhances ovarian cancer cell death via inhibition of glucose transporter-1","volume":"743","author":"Shin","year":"2014","journal-title":"Eur J Pharmacol"},{"key":"B190","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.MCT-06-0722","article-title":"Clofibric acid, a peroxisome proliferator\u2013activated receptor \u03b1 ligand, inhibits growth of human ovarian cancer","volume":"6","author":"Yokoyama","year":"2007","journal-title":"Mol Cancer Ther"},{"key":"B191","doi-asserted-by":"publisher","DOI":"10.1038\/nature25016","article-title":"Alcohol-abuse drug disulfiram targets cancer via p97 segregase adaptor NPL4","volume":"552","author":"Skrott","year":"2017","journal-title":"Nature"},{"key":"B192","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-06-2126","article-title":"Disulfiram, a clinically used anti-alcoholism drug and copper-binding agent, induces apoptotic cell death in breast cancer cultures and xenografts via inhibition of the proteasome activity","volume":"66","author":"Chen","year":"2006","journal-title":"Cancer Res"},{"key":"B193","doi-asserted-by":"publisher","DOI":"10.1007\/s10534-008-9174-3","article-title":"The role of copper in drug-resistant murine and human tumors","volume":"22","author":"Majumder","year":"2009","journal-title":"Biometals"},{"key":"B194","doi-asserted-by":"publisher","DOI":"10.1093\/jb\/mvab045","article-title":"The disulfiram\/copper complex induces apoptosis and inhibits tumour growth in human osteosarcoma by activating the ROS\/JNK signalling pathway","volume":"170","author":"Guo","year":"2021","journal-title":"J Biochem"},{"key":"B195","doi-asserted-by":"publisher","first-page":"110048","DOI":"10.1016\/j.biopha.2020.110048","article-title":"Disulfiram\/copper markedly induced myeloma cell apoptosis through activation of JNK and intrinsic and extrinsic apoptosis pathways","volume":"126","author":"Xu","year":"2020","journal-title":"Biomedicine Pharmacotherapy"},{"key":"B196","doi-asserted-by":"publisher","first-page":"21","DOI":"10.18632\/oncoscience.v1i1","article-title":"Disulfiram\/copper causes redox-related proteotoxicity and concomitant heat shock response in ovarian cancer cells that is augmented by auranofin-mediated thioredoxin inhibition","volume":"1","author":"Papaioannou","year":"2014","journal-title":"Oncoscience"},{"key":"B197","doi-asserted-by":"publisher","first-page":"109371","DOI":"10.1016\/j.biopha.2019.109371","article-title":"Inhibitory effect on ovarian cancer ALDH+ stem-like cells by Disulfiram and Copper treatment through ALDH and ROS modulation","volume":"118","author":"Guo","year":"2019","journal-title":"Biomedicine Pharmacotherapy"},{"key":"B198","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.19881","article-title":"Targeting the cancer stem cell marker, aldehyde dehydrogenase 1, to circumvent cisplatin resistance in NSCLC","volume":"8","author":"MacDonagh","year":"2017","journal-title":"Oncotarget"},{"key":"B199","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2009.09.002","article-title":"Disulfiram\/copper complex inhibiting NF\u03baB activity and potentiating cytotoxic effect of gemcitabine on colon and breast cancer cell lines","volume":"290","author":"Guo","year":"2010","journal-title":"Cancer Lett"},{"key":"B200","doi-asserted-by":"publisher","DOI":"10.1016\/j.bcmd.2011.08.004","article-title":"Disulfiram\/copper complex activated JNK\/c-jun pathway and sensitized cytotoxicity of doxorubicin in doxorubicin resistant leukemia HL60 cells","volume":"47","author":"Xu","year":"2011","journal-title":"Blood Cells Molecules Dis"},{"key":"B201","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1196\/nyas.2008.1138.issue-1","article-title":"Potential inhibition of PDK1\/Akt signaling by phenothiazines suppresses cancer cell proliferation and survival","volume":"1138","author":"Choi","year":"2008","journal-title":"Ann New York Acad Sci"},{"key":"B202","doi-asserted-by":"publisher","first-page":"1360","DOI":"10.3390\/biom12101360","article-title":"Antipsychotic drug fluphenazine against human cancer cells","volume":"12","author":"Duarte","year":"2022","journal-title":"Biomolecules"},{"key":"B203","doi-asserted-by":"publisher","DOI":"10.1158\/1940-6207.CAPR-08-0236","article-title":"Effects of oral contraceptives or a gonadotropin-releasing hormone agonist on ovarian carcinogenesis in genetically engineered mice","volume":"2","author":"Romero","year":"2009","journal-title":"Cancer Prev Res"},{"key":"B204","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajog.2014.10.026","article-title":"Metformin inhibits ovarian cancer growth and increases sensitivity to paclitaxel in mouse models","volume":"212","author":"Lengyel","year":"2015","journal-title":"Am J obstetrics gynecology"},{"key":"B205","doi-asserted-by":"publisher","DOI":"10.2337\/diacare.29.02.06.dc05-1558","article-title":"Increased cancer-related mortality for patients with type 2 diabetes who use sulfonylureas or insulin","volume":"29","author":"Bowker","year":"2006","journal-title":"Diabetes Care"},{"key":"B206","doi-asserted-by":"publisher","DOI":"10.2337\/dc09-1380","article-title":"Metformin associated with lower cancer mortality in type 2 diabetes: ZODIAC-16","volume":"33","author":"Landman","year":"2010","journal-title":"Diabetes Care"},{"key":"B207","doi-asserted-by":"publisher","DOI":"10.2337\/dc08-2175","article-title":"New users of metformin are at low risk of incident cancer: a cohort study among people with type 2 diabetes","volume":"32","author":"Libby","year":"2009","journal-title":"Diabetes Care"},{"key":"B208","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.v119.3","article-title":"Metformin intake is associated with better survival in ovarian cancer: A case-control study","volume":"119","author":"Kumar","year":"2013","journal-title":"Cancer"},{"key":"B209","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1097\/AOG.0b013e3182393ab3","article-title":"Relationship of type II diabetes and metformin use to ovarian cancer progression, survival, and chemosensitivity","volume":"119","author":"Romero","year":"2012","journal-title":"Obstetrics gynecology"},{"key":"B210","doi-asserted-by":"publisher","DOI":"10.1111\/j.1442-2042.2006.01443.x","article-title":"Comparison of 25 and 75 mg\/day naftopidil for lower urinary tract symptoms associated with benign prostatic hyperplasia: a prospective, randomized controlled study","volume":"13","author":"Yokoyama","year":"2006","journal-title":"Int J Urol"},{"key":"B211","doi-asserted-by":"publisher","DOI":"10.1159\/000200787","article-title":"Usefulness of naftopidil for dysuria in benign prostatic hyperplasia and its optimal dose\u2013comparison between 75 and 50 mg","volume":"82","author":"Oh-oka","year":"2009","journal-title":"Urologia Internationalis"},{"key":"B212","doi-asserted-by":"publisher","DOI":"10.1007\/s00345-010-0528-4","article-title":"Clinical efficacy of a loading dose of naftopidil for patients with benign prostate hyperplasia","volume":"29","author":"Funahashi","year":"2011","journal-title":"World J Urol"},{"key":"B213","volume-title":"Implementation of Lifestyle Modifications as First Line Therapies for the Management of Benign Prostatic Hyperplasia","author":"Thomas","year":"2023"},{"key":"B214","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1038\/s41419-020-2588-8","article-title":"Bim, Puma and Noxa upregulation by Naftopidil sensitizes ovarian cancer to the BH3-mimetic ABT-737 and the MEK inhibitor Trametinib","volume":"11","author":"Florent","year":"2020","journal-title":"Cell Death Dis"},{"key":"B215","doi-asserted-by":"publisher","first-page":"99","DOI":"10.3390\/cancers14010099","article-title":"Nelfinavir induces cytotoxicity towards high-grade serous ovarian cancer cells, involving induction of the unfolded protein response, modulation of protein synthesis, DNA damage, lysosomal impairment, and potentiation of toxicity caused by proteasome inhibition","volume":"14","author":"Subeha","year":"2021","journal-title":"Cancers"},{"key":"B216","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199512073332204","article-title":"A preliminary study of ritonavir, an inhibitor of HIV-1 protease, to treat HIV-1 infection","volume":"333","author":"Markowitz","year":"1995","journal-title":"New Engl J Med"},{"key":"B217","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/1476-4598-8-26","article-title":"Ritonavir blocks AKT signaling, activates apoptosis and inhibits migration and invasion in ovarian cancer cells","volume":"8","author":"Kumar","year":"2009","journal-title":"Mol Cancer"},{"key":"B218","article-title":"Ritonavir blocks Akt signaling and exhibits antineoplastic activity in ovarian cancer cell lines","volume":"68","author":"Kumar","year":"2008","journal-title":"Cancer Res"},{"key":"B219","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2013.04.393","article-title":"The HIV protease inhibitor ritonavir induces cell cycle arrest and apoptosis in the A2780 ovarian cancer cell line in vitro and in vivo","volume":"130","author":"Winterhoff","year":"2013","journal-title":"Gynecologic Oncol"},{"key":"B220","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9343(99)00363-0","article-title":"Distribution and expression of cyclooxygenase (COX) isoenzymes, their physiological roles, and the categorization of nonsteroidal anti-inflammatory drugs (NSAIDs)","volume":"107","author":"Wallace","year":"1999","journal-title":"Am J Med"},{"key":"B221","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD001751","article-title":"Nonsteroidal anti-inflammatory drugs for dysmenorrhoea","volume":"2015","author":"Marjoribanks","year":"1996","journal-title":"Cochrane Database systematic Rev"},{"key":"B222","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1111\/papr.2017.17.issue-3","article-title":"Use of nonsteroidal anti-inflammatory drugs for symptomatic treatment of episodic headache","volume":"17","author":"Affaitati","year":"2017","journal-title":"Pain Pract"},{"key":"B223","doi-asserted-by":"publisher","DOI":"10.1016\/j.spinee.2007.10.013","article-title":"Evidence-informed management of chronic low back pain with nonsteroidal anti-inflammatory drugs, muscle relaxants, and simple analgesics","volume":"8","author":"Malanga","year":"2008","journal-title":"Spine J"},{"key":"B224","doi-asserted-by":"publisher","DOI":"10.1038\/nrclinonc.2011.199","article-title":"The role of aspirin in cancer prevention","volume":"9","author":"Thun","year":"2012","journal-title":"Nat Rev Clin Oncol"},{"key":"B225","doi-asserted-by":"publisher","first-page":"djt431","DOI":"10.1093\/jnci\/djt431","article-title":"Aspirin, nonaspirin nonsteroidal anti-inflammatory drug, and acetaminophen use and risk of invasive epithelial ovarian cancer: a pooled analysis in the Ovarian Cancer Association Consortium","volume":"106","author":"Trabert","year":"2014","journal-title":"J Natl Cancer Institute"},{"key":"B226","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-07-0828","article-title":"Extracellular signal-regulated kinase is a target of cyclooxygenase-1-peroxisome proliferator-activated receptor-\u03b4 signaling in epithelial ovarian cancer","volume":"67","author":"Daikoku","year":"2007","journal-title":"Cancer Res"},{"key":"B227","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2014.08.026","article-title":"Modulating cancer multidrug resistance by sertraline in combination with a nanomedicine","volume":"354","author":"Drinberg","year":"2014","journal-title":"Cancer Lett"},{"key":"B228","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1111\/j.1527-3458.2001.tb00188.x","article-title":"The selective serotonin reuptake inhibitor sertraline: its profile and use in psychiatric disorders","volume":"7","author":"MacQueen","year":"2001","journal-title":"CNS Drug Rev"},{"key":"B229","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejphar.2010.08.026","article-title":"Sertraline increases extracellular levels not only of serotonin, but also of dopamine in the nucleus accumbens and striatum of rats","volume":"647","author":"Kitaichi","year":"2010","journal-title":"Eur J Pharmacol"},{"key":"B230","doi-asserted-by":"publisher","DOI":"10.1016\/S0959-437X(96)80091-8","article-title":"P-glycoprotein and multidrug resistance","volume":"6","author":"Gottesman","year":"1996","journal-title":"Curr Opin Genet Dev"},{"key":"B231","doi-asserted-by":"publisher","first-page":"59","DOI":"10.2165\/00003088-200342010-00003","article-title":"Role of P-glycoprotein in pharmacokinetics: clinical implications","volume":"42","author":"Lin","year":"2003","journal-title":"Clin Pharmacokinet"},{"key":"B232","doi-asserted-by":"publisher","DOI":"10.1038\/nrc2789","article-title":"ABC transporters in cancer: more than just drug efflux pumps","volume":"10","author":"Fletcher","year":"2010","journal-title":"Nat Rev Cancer"},{"key":"B233","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(04)16308-3","article-title":"Thalidomide","volume":"363","author":"Franks","year":"2004","journal-title":"Lancet"},{"key":"B234","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2006.04.004","article-title":"Thalidomide and lenalidomide in the treatment of multiple myeloma","volume":"42","author":"Kumar","year":"2006","journal-title":"Eur J Cancer"},{"key":"B235","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejmech.2009.03.018","article-title":"Discovering a new analogue of thalidomide which may be used as a potent modulator of TNF-\u03b1 production","volume":"44","author":"Bra\u00f1a","year":"2009","journal-title":"Eur J medicinal Chem"},{"key":"B236","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1084\/jem.173.3.699","article-title":"Thalidomide selectively inhibits tumor necrosis factor alpha production by stimulated human monocytes","volume":"173","author":"Sampaio","year":"1991","journal-title":"J Exp Med"},{"key":"B237","doi-asserted-by":"publisher","DOI":"10.1684\/ecn.2013.0342","article-title":"Thalidomide distinctly affected TNF-\u03b1, IL-6 and MMP secretion by an ovarian cancer cell line (SKOV-3) and primary ovarian cancer cells","volume":"24","author":"Piura","year":"2013","journal-title":"Eur Cytokine Netw"},{"key":"B238","doi-asserted-by":"publisher","DOI":"10.1038\/bjc.1995.335","article-title":"Effect of thalidomide on tumour necrosis factor production and anti-tumour activity induced by 5, 6-dimethylxanthenone-4-acetic acid","volume":"72","author":"Ching","year":"1995","journal-title":"Br J Cancer"},{"key":"B239","doi-asserted-by":"publisher","DOI":"10.1054\/bjoc.1999.1004","article-title":"Continuous low dose thalidomide: a phase II study in advanced melanoma, renal cell, ovarian and breast cancer","volume":"82","author":"Eisen","year":"2000","journal-title":"Br J Cancer"},{"key":"B240","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2010.08.002","article-title":"Randomized phase III trial of tamoxifen versus thalidomide in women with biochemical-recurrent-only epithelial ovarian, fallopian tube or primary peritoneal carcinoma after a complete response to first-line platinum\/taxane chemotherapy with an evaluation of serum vascular endothelial growth factor (VEGF): A Gynecologic Oncology Group Study","volume":"119","author":"Hurteau","year":"2010","journal-title":"Gynecologic Oncol"},{"key":"B241","doi-asserted-by":"publisher","DOI":"10.1038\/sj.onc.1209232","article-title":"Autocrine activation of PDGFR\u03b1 promotes the progression of ovarian cancer","volume":"25","author":"Matei","year":"2006","journal-title":"Oncogene"},{"key":"B242","doi-asserted-by":"publisher","DOI":"10.2147\/DDDT.S80207","article-title":"The role of dasatinib in the management of chronic myeloid leukemia","volume":"9","author":"Chen","year":"2015","journal-title":"Drug design Dev Ther"},{"key":"B243","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.v116:21","article-title":"Dasatinib induces autophagic cell death in human ovarian cancer","volume":"116","author":"Le","year":"2010","journal-title":"Cancer"},{"key":"B244","doi-asserted-by":"publisher","DOI":"10.3892\/mmr.2015.3784","article-title":"Dasatinib enhances antitumor activity of paclitaxel in ovarian cancer through Src signaling","volume":"12","author":"Xiao","year":"2015","journal-title":"Mol Med Rep"},{"key":"B245","doi-asserted-by":"publisher","first-page":"243","DOI":"10.3390\/cancers11020243","article-title":"Paclitaxel-induced Src activation is inhibited by dasatinib treatment, independently of cancer stem cell properties, in a mouse model of ovarian cancer","volume":"11","author":"Kadife","year":"2019","journal-title":"Cancers"},{"key":"B246","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-0754-03","article-title":"Imatinib mesylate (Gleevec) inhibits ovarian cancer cell growth through a mechanism dependent on platelet-derived growth factor receptor \u03b1 and Akt inactivation","volume":"10","author":"Matei","year":"2004","journal-title":"Clin Cancer Res"},{"key":"B247","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.v110:2","article-title":"A prospective analysis of imatinib-induced c-KIT modulation in ovarian cancer: a phase II clinical study with proteomic profiling","volume":"110","author":"Posadas","year":"2007","journal-title":"Cancer"},{"key":"B248","doi-asserted-by":"publisher","first-page":"784","DOI":"10.1136\/ijgc-00009577-200707000-00005","article-title":"Phase II trial of imatinib mesylate in recurrent, biomarker positive, ovarian cancer (Southwest Oncology Group Protocol S0211)","volume":"17","author":"Alberts","year":"2007","journal-title":"Int J Gynecologic Cancer"},{"key":"B249","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1016\/S0959-8049(00)00228-8","article-title":"Tamoxifen in the treatment of recurrent ovarian carcinoma","volume":"36","author":"Trope","year":"2000","journal-title":"Eur J Cancer"},{"key":"B250","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1016\/j.ygyno.2021.09.024","article-title":"Regorafenib or tamoxifen for platinum-sensitive recurrent ovarian cancer with rising CA125 and no evidence of clinical or RECIST progression: a GINECO randomized phase II trial (REGOVAR)","volume":"164","author":"Tr\u00e9dan","year":"2022","journal-title":"Gynecologic Oncol"},{"key":"B251","article-title":"CA125 response is associated with estrogen receptor expression in a phase II trial of letrozole in ovarian cancer: identification of an endocrine-sensitive subgroup","volume":"8","author":"Bowman","year":"2002","journal-title":"Clin Cancer Res"},{"key":"B252","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-06-2878","article-title":"Antiestrogen therapy is active in selected ovarian cancer cases: the use of letrozole in estrogen receptor\u2013positive patients","volume":"13","author":"Smyth","year":"2007","journal-title":"Clin Cancer Res"},{"key":"B253","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2008.03.014","article-title":"Efficacy of letrozole in the treatment of recurrent platinum-and taxane-resistant high-grade cancer of the ovary or peritoneum","volume":"110","author":"Ramirez","year":"2008","journal-title":"Gynecologic Oncol"},{"key":"B254","doi-asserted-by":"publisher","DOI":"10.1159\/000077436","article-title":"Hormonal therapy with letrozole for relapsed epithelial ovarian cancerLong-term results of a phase II study","volume":"66","author":"Papadimitriou","year":"2004","journal-title":"Oncology"},{"key":"B255","doi-asserted-by":"publisher","first-page":"596","DOI":"10.1016\/j.ygyno.2003.08.021","article-title":"Phase II trial of anastrozole in women with asymptomatic m\u00fcllerian cancer","volume":"91","author":"del Carmen","year":"2003","journal-title":"Gynecologic Oncol"},{"key":"B256","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2014.10.009","article-title":"Ormeloxifene efficiently inhibits ovarian cancer growth","volume":"356","author":"Maher","year":"2015","journal-title":"Cancer Lett"},{"key":"B257","doi-asserted-by":"publisher","DOI":"10.1111\/bcp.14760","article-title":"Model-informed drug repurposing: a pharmacometric approach to novel pathogen preparedness, response and retrospection","volume":"87","author":"Dodds","year":"2021","journal-title":"Br J Clin Pharmacol"},{"key":"B258","doi-asserted-by":"publisher","first-page":"1792","DOI":"10.3390\/pharmaceutics15071792","article-title":"Drug repurposing for targeting myeloid-derived suppressor-cell-generated immunosuppression in ovarian cancer: A literature review of potential candidates","volume":"15","author":"Berckmans","year":"2023","journal-title":"Pharmaceutics"},{"key":"B259","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-020-01374-0","article-title":"Lurbinectedin: first approval","volume":"80","author":"Markham","year":"2020","journal-title":"Drugs"},{"key":"B260","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V99.8.2977","article-title":"The chemokine receptor CCR7 and \u03b14 integrin are important for migration of chronic lymphocytic leukemia cells into lymph nodes","volume":"99","author":"Till","year":"2002","journal-title":"Blood J Am Soc Hematol"},{"key":"B261","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(20)30068-1","article-title":"Lurbinectedin as second-line treatment for patients with small-cell lung cancer: a single-arm, open-label, phase 2 basket trial","volume":"21","author":"Trigo","year":"2020","journal-title":"Lancet Oncol"},{"key":"B262","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-20-3901","article-title":"FDA approval summary: lurbinectedin for the treatment of metastatic small cell lung cancer","volume":"27","author":"Singh","year":"2021","journal-title":"Clin Cancer Res"},{"key":"B263","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0151050","article-title":"Preclinical investigations of PM01183 (lurbinectedin) as a single agent or in combination with other anticancer agents for clear cell carcinoma of the ovary","volume":"11","author":"Takahashi","year":"2016","journal-title":"PloS One"},{"key":"B264","doi-asserted-by":"publisher","first-page":"3134","DOI":"10.1200\/JCO.2018.78.6558","article-title":"Multicenter phase II study of lurbinectedin in BRCA-mutated and unselected metastatic advanced breast cancer and biomarker assessment substudy","volume":"36","author":"Cruz","year":"2018","journal-title":"J Clin Oncol"},{"key":"B265","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-13-1880","article-title":"First-in-human phase I study of Lurbinectedin (PM01183) in patients with advanced solid tumors","volume":"20","author":"Elez","year":"2014","journal-title":"Clin Cancer Res"},{"key":"B266","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(01)00488-0","article-title":"Cyclo-oxygenase 2: a pharmacological target for the prevention of cancer","volume":"2","author":"Dannenberg","year":"2001","journal-title":"Lancet Oncol"},{"key":"B267","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/1471-2407-10-464","article-title":"COX-2 inhibition improves immunotherapy and is associated with decreased numbers of myeloid-derived suppressor cells in mesothelioma","volume":"10","author":"Veltman","year":"2010","journal-title":"Celecoxib influences MDSC Funct BMC Cancer"},{"key":"B268","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.v106:8","article-title":"Decitabine improves patient outcomes in myelodysplastic syndromes: results of a phase III randomized study","volume":"106","author":"Kantarjian","year":"2006","journal-title":"Cancer: Interdiscip Int J Am Cancer Soc"},{"key":"B269","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2002.04.117","article-title":"Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the cancer and leukemia group B","volume":"20","author":"Silverman","year":"2002","journal-title":"J Clin Oncol"},{"key":"B270","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(09)70003-8","article-title":"Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study","volume":"10","author":"Fenaux","year":"2009","journal-title":"Lancet Oncol"},{"key":"B271","doi-asserted-by":"publisher","first-page":"60173","DOI":"10.18632\/oncotarget.18580","article-title":"5-Azacytidine promotes invadopodia formation and tumor metastasis through the upregulation of PI3K in ovarian cancer cells","volume":"8","author":"Cao","year":"2017","journal-title":"Oncotarget"},{"key":"B272","doi-asserted-by":"publisher","DOI":"10.1038\/bjc.2013.10","article-title":"Anticancer efficacy of cisplatin and trichostatin A or 5-aza-2\u2032-deoxycytidine on ovarian cancer","volume":"108","author":"Meng","year":"2013","journal-title":"Br J Cancer"},{"key":"B273","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(14)60958-2","article-title":"Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial","volume":"384","author":"Robert","year":"2014","journal-title":"Lancet"},{"key":"B274","doi-asserted-by":"publisher","first-page":"115724","DOI":"10.1016\/j.bcp.2023.115724","article-title":"Strategies to synergize PD-1\/PD-L1 targeted cancer immunotherapies to enhance antitumor responses in ovarian cancer","volume":"215","author":"Zhao","year":"2023","journal-title":"Biochem Pharmacol"},{"key":"B275","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1002\/cncr.v110:4","article-title":"Inhibitory effect of meloxicam, a selective cyclooxygenase-2 inhibitor, and ciglitazone, a peroxisome proliferator-activated receptor gamma ligand, on the growth of human ovarian cancers","volume":"110","author":"Xin","year":"2007","journal-title":"Cancer: Interdiscip Int J Am Cancer Soc"},{"key":"B276","doi-asserted-by":"publisher","DOI":"10.1007\/s00432-011-0993-1","article-title":"Combination of ciglitazone, a peroxisome proliferator-activated receptor gamma ligand, and cisplatin enhances the inhibition of growth of human ovarian cancers","volume":"137","author":"Yokoyama","year":"2011","journal-title":"J Cancer Res Clin Oncol"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2024.1514120\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,14]],"date-time":"2025-01-14T06:12:56Z","timestamp":1736835176000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2024.1514120\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,14]]},"references-count":276,"alternative-id":["10.3389\/fonc.2024.1514120"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2024.1514120","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,14]]},"article-number":"1514120"}}